Lenacapavir in Clinical Practice – A Primer for Clinicians

In the first webinar of the series, faculty – including principal investigators from the PURPOSE trials – review clinical data and delve into opportunities and challenges for the real-world implementation of lenacapavir as PrEP.

This webinar covers medication administration, managing side effects, potential drug interactions, and transitioning patients on or off lenacapavir as PrEP.

Learning Objectives:

• Summarize the key clinical trial data that supported FDA approval of lenacapavir for HIV prevention.
• Identify appropriate patient populations for lenacapavir as PrEP.
• Explain the administration process, dosing schedule, and monitoring requirements for lenacapavir as PrEP.
• Discuss practical implementation strategies, including counseling points, reimbursement, and barriers to uptake of lenacapavir PrEP.

Faculty:

• Colleen Kelley, MD, MPH, Emory University
• Onyema Ogbuagu, MBBCh, FACP, FIDSA, Yale School of Medicine
• Hyman Scott, MD, MPH, Bridge HIV in the San Francisco Department of Public Health

Related Trainings

Optimizing PrEP in Practice: Guidelines & Clinical Considerations

Dr. Demetre Daskalakis, CDC’s Director of the Division of HIV Prevention, delves into these clinical guidelines and reviews the latest PrEP science. Following his presentation, Dr. Anu Hazra will speak to the clinical considerations of the guidelines from a PrEP provider standpoint.

Learn More

Opportunities and Strategies to Optimize PrEP Uptake in Key Communities

This interactive webinar featured the perspectives of multiple diverse HIV prevention experts on PrEP uptake among relevant consumer/patient communities, including Black women, same-gender-loving (SGL) Black and Latino men, and transgender individuals.

Learn More